◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BCRX

BioCryst Pharmaceuticals Inc (BCRX) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · DATA UPDATED 2026-09-04

BioCryst Pharmaceuticals Inc (BCRX) operates in the DRUG MANUFACTURERS - SPECIALTY & GENERIC industry and is headquartered in Durham, United States with about 435 employees. Its market capitalization is roughly $2 billion. In the fiscal year ended 2025-12-31, BCRX reported $875M in revenue and $264M in net income.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.

Interactive charts & full statements → Open the BCRX valuation workbench →

BCRX Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$941M	$875M	$451M	$331M	$271M	$157M	$18M	$49M	$21M	$25M	$26M	$48M	$14M	$17M	$26M	$20M	$64M	$75M	$57M	$71M	$6M
Gross Profit	$221M	$856M	$438M	$327M	$264M	$150M	$16M	$45M	$20M	$23M	$24M	$46M	$13M	$17M	$26M	$20M	$63M	$70M	$57M	$71M	$6M
Gross Margin %	23.5%	97.8%	97.2%	98.6%	97.6%	95.4%	90.6%	91.6%	97.7%	93.2%	89.8%	96.1%	99.1%	99.4%	99.5%	100.0%	99.9%	93.9%	100.0%	100.0%	100.0%
Operating Income (EBIT)	($313M)	$341M	($3M)	($104M)	($148M)	($178M)	($175M)	($99M)	($94M)	($57M)	($49M)	($39M)	($46M)	($31M)	($34M)	($50M)	($33M)	($14M)	($27M)	($32M)	($47M)
Operating Margin %	-33.3%	39.0%	-0.6%	-31.3%	-54.8%	-113.1%	-981.1%	-203.7%	-456.2%	-228.0%	-184.4%	-81.7%	-336.4%	-177.2%	-128.9%	-252.4%	-52.3%	-18.4%	-48.0%	-45.3%	-756.3%
Net Income	($385M)	$264M	($89M)	($227M)	($247M)	($184M)	($183M)	($109M)	($101M)	($66M)	($55M)	($43M)	($45M)	($30M)	($39M)	($57M)	($33M)	($13M)	($25M)	($29M)	($44M)
Net Margin %	-40.9%	30.2%	-19.7%	-68.4%	-91.2%	-117.1%	-1026.4%	-223.0%	-490.2%	-261.2%	-209.2%	-89.1%	-332.1%	-173.7%	-148.6%	-289.9%	-51.5%	-18.0%	-43.7%	-40.8%	-702.2%
EBITDA	($303M)	$348M	$13M	($116M)	($144M)	($122M)	($168M)	($96M)	($90M)	($57M)	($48M)	($38M)	($40M)	($25M)	($34M)	($52M)	($31M)	($12M)	($23M)	($28M)	($43M)
Earnings Per Share (EPS)	$-1.50	$1.21	$-0.43	$-1.18	$-1.33	$-1.03	$-1.09	$-0.94	$-0.98	$-0.78	$-0.75	$-0.59	$-0.68	$-0.55	$-0.79	$-1.26	$-0.73	$-0.35	$-0.65	$-0.89	$-1.50
Shares Outstanding (M)	265M	219M	207M	192M	186M	179M	167M	116M	103M	84M	74M	73M	67M	55M	49M	45M	45M	39M	38M	33M	29M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BCRX Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	$218M	$156M	$407M	$159M	$163M	$146M	$132M	$117M
Gross Profit	$214M	($547M)	$397M	$157M	$161M	$141M	$125M	$114M
Gross Margin %	98.2%	-349.5%	97.6%	98.4%	98.3%	96.9%	95.3%	97.2%
Operating Income (EBIT)	$98M	($702M)	$260M	$30M	$30M	$21M	($5M)	$8M
Operating Margin %	45.1%	-448.6%	64.0%	18.6%	18.2%	14.6%	-3.4%	6.6%
Net Income	$78M	($722M)	$246M	$13M	$5M	$0M	($27M)	($14M)
Net Margin %	35.9%	-461.5%	60.5%	8.1%	3.1%	0.0%	-20.4%	-12.0%
EBITDA	$99M	($700M)	$266M	$32M	$28M	$25M	($1M)	$12M
Earnings Per Share (EPS)	$0.30	$-2.98	$1.12	$0.06	$0.02	$0.00	$-0.13	$-0.07
Shares Outstanding (M)	265M	242M	219M	220M	220M	215M	207M	207M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BCRX Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$360M	$330M	($52M)	($95M)	($162M)	($142M)	($137M)	($90M)	($93M)	($41M)	($53M)	($13M)	($39M)	($27M)	($37M)	($32M)	($29M)	($16M)	($21M)	($25M)	($15M)
Capital Expenditures (CapEx)	$3M	$2M	$1M	$2M	$1M	$2M	$1M	$0M	$0M	$0M	$5M	$5M	$0M	$0M	$0M	$0M	$0M	$1M	$1M	$3.3B	$2M
Free Cash Flow (FCF)	$357M	$327M	($53M)	($97M)	($163M)	($145M)	($138M)	($90M)	($93M)	($41M)	($59M)	($18M)	($39M)	($27M)	($38M)	($32M)	($29M)	($17M)	($22M)	($3.4B)	($17M)
FCF Margin %	38.0%	37.4%	-11.8%	-29.4%	-60.3%	-92.0%	-773.2%	-184.1%	-450.0%	-164.7%	-222.8%	-37.8%	-284.1%	-153.2%	-142.7%	-164.5%	-45.5%	-22.6%	-39.1%	-4729.0%	-269.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BCRX Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	$104M	($62M)	$276M	$42M	$41M	($28M)	($5M)	$8M
Capital Expenditures (CapEx)	$0M	$0M	$1M	$1M	$0M	$0M	$1M	$0M
Free Cash Flow (FCF)	$104M	($63M)	$275M	$40M	$41M	($28M)	($6M)	$8M
FCF Margin %	47.7%	-40.0%	67.7%	25.3%	25.2%	-19.0%	-4.5%	7.0%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BCRX Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$558M	$514M	$490M	$517M	$550M	$588M	$335M	$175M	$147M	$178M	$90M	$125M	$137M	$49M	$57M	$82M	$111M	$142M	$85M	$143M	$68M
Cash & Cash Equivalents	$155M	$90M	$105M	$111M	$305M	$504M	$272M	$114M	$27M	$50M	$22M	$29M	$55M	$21M	$21M	$16M	$14M	$41M	$22M	$31M	$4M
Total Liabilities	$1.0B	$633M	$966M	$972M	$845M	$695M	$354M	$137M	$98M	$94M	$88M	$77M	$61M	$50M	$58M	$67M	$44M	$56M	$38M	$78M	$47M
Total Debt (Short + Long-Term)	$781M	$429M	$831M	$814M	$736M	$587M	$151M	$81M	$59M	$52M	$51M	$30M	$30M	$30M	$30M	$30M	$0M	$0M	$9M	$0M	$0M
Total Shareholders' Equity	($454M)	($119M)	($476M)	($456M)	($295M)	($107M)	($19M)	$38M	($732M)	($632M)	($566M)	($511M)	($468M)	($423M)	($393M)	$15M	$67M	$86M	$46M	$65M	$21M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BCRX viewer.

Other Companies in DRUG MANUFACTURERS - SPECIALTY & GENERIC

INDV · Indivior PLC Ordinary Shares — $4 billion
RGC · Regencell Bioscience Holdings Ltd — $3 billion
SUPN · Supernus Pharmaceuticals Inc — $2 billion
HCM · HUTCHMED DRC — $2 billion
TRLV · Trulieve Cannabis Corp. — $2 billion
PBH · Prestige Brand Holdings Inc — $2 billion
BHC · Bausch Health Companies Inc — $2 billion
ALVO · Alvotech — $2 billion

← BCRP All “B” companies BCS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.